Metabiomics

Metabiomics is developing a non-invasive screening test for earlier and more accurate detection of colon polyps and colorectal cancer (CRC) based on human microbiome biomarkers. Our test has the potential to dislodge colonoscopy as the gold-standard for CRC screening, and to dramatically reduce the burden of CRC in terms of healthcare costs, morbidity and mortality. CRC is the 2nd biggest cancer killer in the US, causing 55k deaths/year and $14B in annual health care costs. We have developed patented/pending technology that integrates advances in microbial ecology, DNA sequencing, and computational systems biology that enables us to detect cancer and small colon polyps by sequencing the microbial DNA in stool samples. Our approach is novel, accurate (97% sensitivity), and extremely cost effective.